Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he ...

The analyst is thus maintaining a cautious stance on the stock. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...